ORIGINAL RESEARCH article
Front. Med.
Sec. Pulmonary Medicine
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1506621
Efficacy and safety analysis of montelukast sodium added on azithromycin in the treatment of mycoplasma pneumoniae pneumonia in children
Provisionally accepted
Ying Liang1
Wei Li2*- 1Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, Shanghai Municipality, China
- 2Shanghai General Hospital, Shanghai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective To evaluate the safety and effectiveness of using montelukast sodium added on azithromycin for the treatment of pediatric mycoplasma pneumoniae pneumonia (MPP).Methods Retrospective analysis showed that 122 children with MPP were divided into a control group (61 cases received azithromycin treatment) and a study group (61 cases received azithromycin combined with montelukast sodium treatment) according to different treatment plans. Both groups were treated for 7 days, and lung function, lung compliance, chest CT signal, inflammatory immune status, and side effects were compared before and after treatment.Result After a month of treatment, positive end expiratory pressure (PEEP) levels were lower in the research group compared to the control group's kids, whereas forced vital capacity (FVC), tidal volume (TV), peak expiratory flow rate (PEF), pulmonary ventilation per minute (MVV), and pulmonary dynamic compliance (Cdyn) levels were greater (P < 0.05). After a month of treatment, the detection rates of lung CT signs such as bronchial wall thickening, pleural effusion (PE), ground glass density shadow (GGO), gravel sign, lymphadenopathy, consolidation of lung (LC) and bronchogenic sign in the research group were all lower than those in the control group (P < 0.05). Compared to the control group, serum levels of amyloid A (SAA), procalcitonin (PCT), lactate dehydrogenase (LDH), TOll-like receptor 4 (TLR4), and CD8+ were all lower in the research group.Azithromycin plus montelukast sodium can effectively improve the lung function and lung compliance of children with MPP, reduce the detection rate of chest CT signs of disease symptoms, and improve the inflammatory and immune state of the body, without increasing adverse reactions, and the clinical application is safe.
Keywords: Mycoplasma pneumoniae pneumonia, Azithromycin, montelukast sodium, Therapeutic effect, security
Received: 27 Nov 2024; Accepted: 13 Jun 2025.
Copyright: © 2025 Liang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Wei Li, Shanghai General Hospital, Shanghai, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.